[go: up one dir, main page]

AR065878A1 - Agente con blanco en una celula cancerosa y un fibroblasto asociado a cancer - Google Patents

Agente con blanco en una celula cancerosa y un fibroblasto asociado a cancer

Info

Publication number
AR065878A1
AR065878A1 ARP080101305A ARP080101305A AR065878A1 AR 065878 A1 AR065878 A1 AR 065878A1 AR P080101305 A ARP080101305 A AR P080101305A AR P080101305 A ARP080101305 A AR P080101305A AR 065878 A1 AR065878 A1 AR 065878A1
Authority
AR
Argentina
Prior art keywords
cancer
cell
agent
group
fibroblast
Prior art date
Application number
ARP080101305A
Other languages
English (en)
Inventor
Rishu Takimoto
Yoshiro Niitsu
Original Assignee
Yoshiro Niitsu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yoshiro Niitsu filed Critical Yoshiro Niitsu
Publication of AR065878A1 publication Critical patent/AR065878A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/04—Uses of viruses as vector in vivo
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/10—Vectors comprising a non-peptidic targeting moiety

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Droga para el tratamiento del cáncer y un método para el tratamiento del mismo. Este objeto puede ser alcanzado mediante un agente, que contiene un retinoide, con blanco en o direccionado a una célula seleccionada a partir del grupo que consiste deuna célula cancerosa y un fibroblasto asociado a cáncer, un portador de entrega de sustancia hacia la célula, el portador conteniendo el agente direccionado, una composicion anti-cáncer, una composicion anti-fibroblasto asociado a cáncer, y unmétodo de tratamiento de cáncer que utiliza el agente direccionado o el portador. Reivindicacion 1: Un agente direccionado a una célula seleccionada a partir del grupo que consiste de una célula cancerosa y un fibroblasto asociado a cáncer,comprendiendo el agente direccionado un retinoide. Reivindicacion 2: El agente direccionado de acuerdo con la reivindicacion 1, en donde el retinoide comprende retinol. Reivindicacion 9: La composicion de acuerdo con cualquiera de lasreivindicaciones 6 a 8, en donde la droga que controla la actividad o crecimiento de un fibroblasto asociado a cáncer está seleccionada a partir del grupo que consiste de un inhibidor de la actividad o produccion de una sustancia bioactivaseleccionada a partir del grupo que consiste de TGF-beta, HGF, PDGF, VEGF, IGF, MMP, FGF, uPA, catepsina, y SDF-1, un supresor de la actividad celular, un inhibidor de crecimiento, un inductor de apoptosis, y un siRNA, ribozima, ácido nucleicoantisentido, polinucleotido quimérico de DNA/RNA, o vector que expresa el mismo, que se direcciona a una o más moléculas de entre una molécula constituyente de la matriz extracelular producida por fibroblastos asociados a cáncer y una moléculainvolucrada en la produccion o secrecion de la molécula constituyente de la matriz extracelular. Reivindicacion 10: La composicion de acuerdo con la reivindicacion 9, en donde la molécula involucrada en la produccion o secrecion de la moléculaconstituyente de la matriz extracelular es HSP47.
ARP080101305A 2007-03-30 2008-03-28 Agente con blanco en una celula cancerosa y un fibroblasto asociado a cancer AR065878A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007091808 2007-03-30
JP2007261202 2007-10-04
JP2007324459 2007-12-17

Publications (1)

Publication Number Publication Date
AR065878A1 true AR065878A1 (es) 2009-07-08

Family

ID=39808395

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080101305A AR065878A1 (es) 2007-03-30 2008-03-28 Agente con blanco en una celula cancerosa y un fibroblasto asociado a cancer

Country Status (11)

Country Link
US (2) US8686052B2 (es)
EP (1) EP2135600B1 (es)
JP (4) JP5302187B2 (es)
KR (1) KR101585947B1 (es)
CN (1) CN101674810B (es)
AR (1) AR065878A1 (es)
AU (1) AU2008233550B2 (es)
CA (1) CA2682493A1 (es)
ES (1) ES2793673T3 (es)
TW (1) TWI407971B (es)
WO (1) WO2008120815A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7685050B2 (en) * 2001-12-13 2010-03-23 Bgc Partners, Inc. Systems and methods for improving the liquidity and distribution network for luxury and other illiquid items
US7358223B2 (en) * 2004-10-04 2008-04-15 Nitto Denko Corporation Biodegradable cationic polymers
US20120269886A1 (en) 2004-12-22 2012-10-25 Nitto Denko Corporation Therapeutic agent for pulmonary fibrosis
DK1842557T3 (da) 2004-12-22 2013-12-02 Nitto Denko Corp Lægemiddelbærer og lægemiddelbærerkit til inhibition af fibrose
JP2009221164A (ja) * 2008-03-17 2009-10-01 Nitto Denko Corp 肺線維症処置剤
JP5342834B2 (ja) * 2008-09-05 2013-11-13 日東電工株式会社 骨髄線維症処置剤
US9572886B2 (en) 2005-12-22 2017-02-21 Nitto Denko Corporation Agent for treating myelofibrosis
TWI407971B (zh) * 2007-03-30 2013-09-11 Nitto Denko Corp Cancer cells and tumor-related fibroblasts
US20080312174A1 (en) * 2007-06-05 2008-12-18 Nitto Denko Corporation Water soluble crosslinked polymers
AU2008298592A1 (en) * 2007-09-14 2009-03-19 Nitto Denko Corporation Drug carriers
RU2596495C2 (ru) * 2008-09-12 2016-09-10 Нитто Денко Корпорейшн Визуализирующие агенты для фиброзных заболеваний
CN102933233A (zh) * 2010-06-17 2013-02-13 日东电工株式会社 肾纤维化处理剂
JP5950428B2 (ja) 2010-08-05 2016-07-13 日東電工株式会社 線維化組織から正常組織を再生するための組成物
JP2014500258A (ja) * 2010-11-15 2014-01-09 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション 制御放出粘膜付着システム
BR112013033072B1 (pt) 2011-06-21 2021-04-13 Nitto Denko Corporation Uso de um agente
RU2637372C2 (ru) * 2011-11-18 2017-12-04 Нитто Денко Корпорейшн Средство для лечения фиброза кишечника
JP6340162B2 (ja) 2012-12-20 2018-06-06 日東電工株式会社 アポトーシス誘導剤
JP6076076B2 (ja) 2012-12-21 2017-02-08 日東電工株式会社 組織再生促進剤
WO2014169395A1 (en) * 2013-04-19 2014-10-23 University Of Saskatchewan Aromatase inhibitor-releasing intravaginal device
US10471267B2 (en) 2013-05-06 2019-11-12 Medtronic, Inc. Implantable cardioverter-defibrillator (ICD) system including substernal lead
US10668270B2 (en) 2013-05-06 2020-06-02 Medtronic, Inc. Substernal leadless electrical stimulation system
US10556117B2 (en) 2013-05-06 2020-02-11 Medtronic, Inc. Implantable cardioverter-defibrillator (ICD) system including substernal pacing lead
CN104374918B (zh) * 2013-08-17 2016-11-09 复旦大学 热休克蛋白47胶质瘤相关肿瘤抗原及应用
US20170173005A1 (en) 2014-03-27 2017-06-22 Research Foundation Of The City University Of New York Method for detecting or treating triple negative breast cancer
WO2015152332A1 (ja) 2014-04-02 2015-10-08 日東電工株式会社 標的化分子およびその使用
JP6480467B2 (ja) 2014-04-07 2019-03-13 日東電工株式会社 疎水性薬物送達のための新規なポリマーベースのヒドロトロープ
EP3159009B1 (en) 2014-06-17 2021-10-27 Nitto Denko Corporation Inhibitors of gst-pi and rb1cc1 for use in the treatment of cancer
US10792299B2 (en) 2014-12-26 2020-10-06 Nitto Denko Corporation Methods and compositions for treating malignant tumors associated with kras mutation
US11045488B2 (en) 2014-12-26 2021-06-29 Nitto Denko Corporation RNA interference agents for GST-π gene modulation
US10264976B2 (en) 2014-12-26 2019-04-23 The University Of Akron Biocompatible flavonoid compounds for organelle and cell imaging
US20180002702A1 (en) 2014-12-26 2018-01-04 Nitto Denko Corporation Methods and compositions for treating malignant tumors associated with kras mutation
CN104825394B (zh) * 2015-04-17 2018-08-17 北京大学 靶向肿瘤相关成纤维细胞的脂质体载药系统
US10792374B2 (en) 2015-10-09 2020-10-06 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
US10358647B2 (en) 2015-12-13 2019-07-23 Nitto Denko Corporation siRNA structures for high activity and reduced off target
US11260132B2 (en) 2017-03-16 2022-03-01 Children's Medical Center Corporation Engineered liposomes as cancer-targeted therapeutics
EP3848050A4 (en) * 2018-08-22 2022-06-08 Nitto Denko Corporation DRUG USING AN HSP47 INHIBITOR TO INCREASE SENSITIVITY TO A CHEMOTHERAPY DRUG
KR102173702B1 (ko) 2018-11-27 2020-11-03 가톨릭대학교 산학협력단 피부 세포 표적용 펩타이드 및 이의 용도
RU2733230C1 (ru) * 2019-12-16 2020-09-30 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Петрова" Министерства здравоохранения Российской Федерации КЛЕТОЧНАЯ ЛИНИЯ РАКА МОЧЕВОГО ПУЗЫРЯ ЧЕЛОВЕКА 198 BlCan RLA
RU2742244C1 (ru) * 2020-05-20 2021-02-04 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Петрова" Министерства здравоохранения Российской Федерации КЛЕТОЧНАЯ ЛИНИЯ РАКА МОЧЕВОГО ПУЗЫРЯ ЧЕЛОВЕКА 587 BlCan TVV
RU2742245C1 (ru) * 2020-05-20 2021-02-04 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Петрова" Министерства здравоохранения Российской Федерации КЛЕТОЧНАЯ ЛИНИЯ РАКА МОЧЕВОГО ПУЗЫРЯ ЧЕЛОВЕКА 398 BlCan KAE
JP7327855B2 (ja) * 2020-06-26 2023-08-16 ラクオリア創薬株式会社 レチノイドとがん治療薬との併用療法が有効ながん患者の選択方法およびレチノイドとがん治療薬との併用医薬
KR20230072259A (ko) 2021-11-17 2023-05-24 사회복지법인 삼성생명공익재단 Prrx1 억제제를 포함하는 암 예방 또는 치료용 약학 조성물

Family Cites Families (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4665913A (en) * 1983-11-17 1987-05-19 Lri L.P. Method for ophthalmological surgery
US4669466A (en) * 1985-01-16 1987-06-02 Lri L.P. Method and apparatus for analysis and correction of abnormal refractive errors of the eye
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US5811119A (en) 1987-05-19 1998-09-22 Board Of Regents, The University Of Texas Formulation and use of carotenoids in treatment of cancer
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5733572A (en) 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US6610841B1 (en) 1997-12-18 2003-08-26 Gilead Sciences, Inc. Nucleotide-based prodrugs
US5258791A (en) * 1990-07-24 1993-11-02 General Electric Company Spatially resolved objective autorefractometer
US6746678B1 (en) 1991-02-22 2004-06-08 Howard K. Shapiro Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5144630A (en) * 1991-07-29 1992-09-01 Jtt International, Inc. Multiwavelength solid state laser using frequency conversion techniques
CA2073802C (en) * 1991-08-16 2003-04-01 John Shimmick Method and apparatus for combined cylindrical and spherical eye corrections
US5472954A (en) 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
DE4232915A1 (de) * 1992-10-01 1994-04-07 Hohla Kristian Vorrichtung zur Formung der Cornea durch Abtragen von Gewebe
US5583020A (en) 1992-11-24 1996-12-10 Ribozyme Pharmaceuticals, Inc. Permeability enhancers for negatively charged polynucleotides
US5520679A (en) * 1992-12-03 1996-05-28 Lasersight, Inc. Ophthalmic surgery method using non-contact scanning laser
US5820879A (en) 1993-02-12 1998-10-13 Access Pharmaceuticals, Inc. Method of delivering a lipid-coated condensed-phase microparticle composition
US5753261A (en) 1993-02-12 1998-05-19 Access Pharmaceuticals, Inc. Lipid-coated condensed-phase microparticle composition
US5785976A (en) 1993-03-05 1998-07-28 Pharmacia & Upjohn Ab Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof
US5460627A (en) * 1993-05-03 1995-10-24 O'donnell, Jr.; Francis E. Method of evaluating a laser used in ophthalmological surgery
CO4230054A1 (es) * 1993-05-07 1995-10-19 Visx Inc Metodo y sistemas para tratamiento con laser de errores refractivos utilizando formacion de imagenes de desplazamiento
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5942230A (en) 1994-05-06 1999-08-24 The United States Of America As Represented By The Department Of Health And Human Services Composition of immunotoxins and retinoids and use thereof
JPH08180824A (ja) * 1994-12-22 1996-07-12 Hitachi Ltd 電子線源、その製造方法、電子線源装置及びそれを用いた電子線装置
US5646791A (en) * 1995-01-04 1997-07-08 Visx Incorporated Method and apparatus for temporal and spatial beam integration
US5534261A (en) 1995-01-17 1996-07-09 University Of Southern California Retinoid-based compositions and method for preventing adhesion formation using the same
US6187315B1 (en) 1995-03-03 2001-02-13 Atajje, Inc. Compositions and methods of treating cancer with tannin complexes
US5666117A (en) * 1995-08-31 1997-09-09 The United State Of American As Represented By The Secretary Of The Navy Non-Return to Zero Level to Bi-Phase signal converter
US6120794A (en) 1995-09-26 2000-09-19 University Of Pittsburgh Emulsion and micellar formulations for the delivery of biologically active substances to cells
US5782822A (en) * 1995-10-27 1998-07-21 Ir Vision, Inc. Method and apparatus for removing corneal tissue with infrared laser radiation
IL126179A (en) 1996-03-12 2003-04-10 Pg Txl Co Lp Pharmaceutical compositions containing anti-tumor drug conjugates
US6441025B2 (en) 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
US6238917B1 (en) 1996-04-02 2001-05-29 Commonwealth Scientific Industrial Research Organizaion Asymmetric hammerhead ribozymes
US5742626A (en) * 1996-08-14 1998-04-21 Aculight Corporation Ultraviolet solid state laser, method of using same and laser surgery apparatus
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6331289B1 (en) 1996-10-28 2001-12-18 Nycomed Imaging As Targeted diagnostic/therapeutic agents having more than one different vectors
US20010041884A1 (en) * 1996-11-25 2001-11-15 Frey Rudolph W. Method for determining and correcting vision
US6271914B1 (en) * 1996-11-25 2001-08-07 Autonomous Technologies Corporation Objective measurement and correction of optical systems using wavefront analysis
US5777719A (en) * 1996-12-23 1998-07-07 University Of Rochester Method and apparatus for improving vision and the resolution of retinal images
US6090102A (en) * 1997-05-12 2000-07-18 Irvision, Inc. Short pulse mid-infrared laser source for surgery
FR2763853B1 (fr) 1997-05-28 2000-01-07 Oreal Association d'un retinoide avec un polymere polyamine
CA2242035C (en) 1997-07-01 2004-11-23 Transgene S.A. Compositions useful for transferring therapeutically active substances into a target cell, and their use in gene therapy
US6037481A (en) 1997-08-08 2000-03-14 Industria E Comercio De Cosmeticos Natura Ltda Process for stabilizing levogyre ascorbic acid (LAA), a stable aqueous LAA composition, a process for preparing a stable topical solution, an emulsion, a vitamin product, and a method for cosmetic, pharmaceutical or nutritional treatment
US6072101A (en) 1997-11-19 2000-06-06 Amcol International Corporation Multicomponent superabsorbent gel particles
AU4193199A (en) 1998-05-20 1999-12-06 Expression Genetics, Inc. A hepatocyte targeting polyethylene glyco-grafted poly-l-lysine polymeric gene carrier
US6099125A (en) * 1998-12-07 2000-08-08 Schepens Eye Research Foundation Coaxial spatially resolved refractometer
US6000800A (en) * 1998-06-22 1999-12-14 Schepens Eye Research Institute Coaxial spatially resolved refractometer
US6004313A (en) * 1998-06-26 1999-12-21 Visx, Inc. Patient fixation system and method for laser eye surgery
GB9814527D0 (en) 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
US6347549B1 (en) * 1998-07-09 2002-02-19 Ryan International Corporation Enhancement of storm location from a single moving platform
EP1117720A4 (en) 1998-07-13 2001-11-14 Expression Genetics Inc POLYESTER POLY-L-LYSINE ANALOG USED AS A BIODEGRADABLE SOLUBLE GENE CONVEYOR
CN1205922C (zh) 1998-07-24 2005-06-15 柳署弘 制备含有胆汁酸的澄清水溶液剂型
KR100274842B1 (ko) 1998-10-01 2001-03-02 김효근 미립구를 이용한 레티노익산의 서방형 약물방출 시스템
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
FR2790405B1 (fr) 1999-03-02 2001-04-20 Oreal Nanocapsules a base de polymeres dendritiques
US6245059B1 (en) * 1999-04-07 2001-06-12 Visx, Incorporated Offset ablation profiles for treatment of irregular astigmation
US6328988B1 (en) 1999-04-23 2001-12-11 Rutgers, The State University Of New Jersey Hyperbranched polymeric micelles for encapsulation and delivery of hydrophobic molecules
US6887468B1 (en) 1999-04-28 2005-05-03 Board Of Regents, The University Of Texas System Antibody kits for selectively inhibiting VEGF
US7276348B2 (en) 1999-04-30 2007-10-02 Regents Of The University Of Michigan Compositions and methods relating to F1F0-ATPase inhibitors and targets thereof
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6050687A (en) * 1999-06-11 2000-04-18 20/10 Perfect Vision Optische Geraete Gmbh Method and apparatus for measurement of the refractive properties of the human eye
US7098030B2 (en) 1999-12-31 2006-08-29 Mirus Bio Corporation Polyampholytes for delivering polyions to a cell
US20020041898A1 (en) 2000-01-05 2002-04-11 Unger Evan C. Novel targeted delivery systems for bioactive agents
US6234631B1 (en) * 2000-03-09 2001-05-22 Lasersight Technologies, Inc. Combination advanced corneal topography/wave front aberration measurement
KR20010100194A (ko) 2000-03-13 2001-11-14 박호군 여러 가지 물질의 가용화용 조성물과 제형 및 그들의제조방법
DE10012151A1 (de) 2000-03-13 2001-09-27 Gsf Forschungszentrum Umwelt Mittel zur Behandlung von Erkrankungen des Tracheo-Brochialtraktes, insbesondere der COPD
US6673062B2 (en) * 2000-03-14 2004-01-06 Visx, Inc. Generating scanning spot locations for laser eye surgery
EP1267834A4 (en) 2000-03-29 2003-08-27 Aradigm Corp CATIONIC LIPOSOMES
JP4515687B2 (ja) * 2000-04-19 2010-08-04 アルコン・レフラクティヴ・ホライズンズ・インク． 眼のレジストレーション及び乱視のアライメント制御システム及び方法
US6338559B1 (en) * 2000-04-28 2002-01-15 University Of Rochester Apparatus and method for improving vision and retinal imaging
EP1280757B1 (en) 2000-05-02 2005-08-17 F. Hoffmann-La Roche Ag New gamma selective retinoids
US6896890B2 (en) 2000-05-05 2005-05-24 R.P. Scherer Technologies, Inc. Oil-in-water emulsion formulation containing free and entrapped hydroquinone and retinol
US6460997B1 (en) * 2000-05-08 2002-10-08 Alcon Universal Ltd. Apparatus and method for objective measurements of optical systems using wavefront analysis
US6471968B1 (en) 2000-05-12 2002-10-29 Regents Of The University Of Michigan Multifunctional nanodevice platform
ATE453718T1 (de) * 2000-08-29 2010-01-15 Genentech Inc Verfahren zur verbesserung von krebstherapie
US6696038B1 (en) 2000-09-14 2004-02-24 Expression Genetics, Inc. Cationic lipopolymer as biocompatible gene delivery agent
US20040142474A1 (en) 2000-09-14 2004-07-22 Expression Genetics, Inc. Novel cationic lipopolymer as a biocompatible gene delivery agent
US7276249B2 (en) 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
WO2002028387A1 (en) * 2000-10-03 2002-04-11 Oncopharmaceutical, Inc. Inhibitors of angiogenesis and tumor growth for local and systemic administration
US6998115B2 (en) 2000-10-10 2006-02-14 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
US7427394B2 (en) 2000-10-10 2008-09-23 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
WO2002032413A2 (en) * 2000-10-17 2002-04-25 Board Of Regents, The University Of Texas System A method to incorporate n-(4-hydroxyphenyl) retinamide in liposomes
US7265186B2 (en) 2001-01-19 2007-09-04 Nektar Therapeutics Al, Corporation Multi-arm block copolymers as drug delivery vehicles
TWI246524B (en) 2001-01-19 2006-01-01 Shearwater Corp Multi-arm block copolymers as drug delivery vehicles
US6652886B2 (en) 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
WO2002066646A2 (en) 2001-02-16 2002-08-29 Incyte Genomics, Inc. Neurotransmission-associated proteins
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
JP2004524371A (ja) 2001-04-13 2004-08-12 ザ・ポピュレイション・カウンシル，インコーポレイテッド 核レセプターを介するペプチド核酸の細胞核内導入
US6472954B1 (en) * 2001-04-23 2002-10-29 Agilent Technologies, Inc. Controlled effective coupling coefficients for film bulk acoustic resonators
US6582079B2 (en) * 2001-06-05 2003-06-24 Metrologic Instruments, Inc. Modular adaptive optical subsystem for integration with a fundus camera body and CCD camera unit and improved fundus camera employing same
JP4547696B2 (ja) 2001-06-07 2010-09-22 第一三共株式会社 肝硬変予防・治療剤
KR20040029359A (ko) 2001-07-12 2004-04-06 루트거스, 더 스테이트 유니버시티 오브 뉴 저지 약물 전달을 위한 양친매성 별모양 거대분자
US6586524B2 (en) 2001-07-19 2003-07-01 Expression Genetics, Inc. Cellular targeting poly(ethylene glycol)-grafted polymeric gene carrier
US7101995B2 (en) 2001-08-27 2006-09-05 Mirus Bio Corporation Compositions and processes using siRNA, amphipathic compounds and polycations
PT1443912E (pt) 2001-10-12 2007-11-28 Elan Pharma Int Ltd Composições tendo uma combinação de características de libertação imediata e de libertação controlada
US7297515B1 (en) 2001-10-26 2007-11-20 Myriad Genetics, Inc. Zinc finger proteins
US20030161791A1 (en) 2001-10-30 2003-08-28 Bentley Michael David Water-soluble polymer conjugates of retinoic acid
WO2003044188A1 (en) 2001-11-21 2003-05-30 Mitsubishi Chemical Corporation Method of inhibiting gene expression
JP3803318B2 (ja) 2001-11-21 2006-08-02 株式会社ＲＮＡｉ 遺伝子発現阻害方法
US7060498B1 (en) 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
US6637884B2 (en) * 2001-12-14 2003-10-28 Bausch & Lomb Incorporated Aberrometer calibration
US20030147958A1 (en) 2002-01-29 2003-08-07 Cheol-Hee Ahn Biodegradable multi-block copolymers of poly(amino acid)s and poly(ethylene glycol) for the delivery of bioactive agents
MXPA04007576A (es) * 2002-02-11 2004-11-10 Visx Inc Sistema y metodo de ciclo cerrado para la ablacion de lentes con aberraciones.
US20040106125A1 (en) 2002-02-15 2004-06-03 Duggan Brendan M Neurotransmission-associated proteins
US7018655B2 (en) 2002-03-18 2006-03-28 Labopharm, Inc. Amphiphilic diblock, triblock and star-block copolymers and their pharmaceutical compositions
US6740676B2 (en) 2002-03-19 2004-05-25 Allergan, Inc. 4-[(8-ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-benzoic and 2-[4-[(8-ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-phenyl]-acetic acid, their esters and salts having cytochrome p450rai inhibitory activity
US7101576B2 (en) 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
US20030215395A1 (en) 2002-05-14 2003-11-20 Lei Yu Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier
JP4814520B2 (ja) * 2002-05-15 2011-11-16 エンドサイト，インコーポレイテッド ビタミン−マイトマイシン結合体
ATE488530T1 (de) 2002-06-19 2010-12-15 Raven Biotechnologies Inc Internalisierende antikörper spezifisch für das raag10 zelloberflächenziel
US7071163B2 (en) 2002-08-05 2006-07-04 Mirus Bio Corporation Compounds for targeting hepatocytes in vivo
JP2004083436A (ja) 2002-08-23 2004-03-18 Minofuaagen Seiyaku:Kk 星細胞活性化抑制剤、及び、臓器線維症の予防又は治療剤
US20050191302A1 (en) 2002-08-29 2005-09-01 University Of Southampton Treatment for liver disease
US6740336B2 (en) 2002-10-04 2004-05-25 Mirus Corporation Process for generating multilayered particles
JP4757493B2 (ja) 2002-11-13 2011-08-24 レイベン バイオテクノロジーズ，インコーポレイティド 抗原ｐｉｐａおよびそれに結合する抗体
EP1581583B1 (en) 2002-12-30 2010-03-24 Nektar Therapeutics Multi-arm polypeptide-poly(ethylene glycol) block copolymers as drug delivery vehicles
US20040138154A1 (en) 2003-01-13 2004-07-15 Lei Yu Solid surface for biomolecule delivery and high-throughput assay
CA2488224A1 (en) * 2003-04-03 2004-10-21 Alnylam Pharmaceuticals, Inc. Irna conjugates
US20050002999A1 (en) * 2003-06-04 2005-01-06 Rahul Mehta Long-circulating liposomal compositions
DE602004019546D1 (de) 2003-08-26 2009-04-02 Smithkline Beecham Corp Heterofunktionelle copolymere von glycerol und polyethylenglykol, ihre konjugate und zusammensetzungen
MXPA06003014A (es) 2003-09-18 2006-06-23 Raven Biotechnologies Inc Kid3 y anticuerpos de kid3 que se unen a este.
US7064127B2 (en) 2003-12-19 2006-06-20 Mount Sinai School Of Medicine Of New York University Treatment of hepatic fibrosis with imatinib mesylate
CN1917859A (zh) * 2003-12-24 2007-02-21 日本株式会社Ltt生物医药 载药纳米微粒及其制备方法以及含有该纳米微粒的非肠道给药用制剂
WO2006085987A2 (en) 2004-07-09 2006-08-17 University Of Iowa Research Foundation Rna interference in respiratory epitheial cells
US7358223B2 (en) 2004-10-04 2008-04-15 Nitto Denko Corporation Biodegradable cationic polymers
US8057821B2 (en) 2004-11-03 2011-11-15 Egen, Inc. Biodegradable cross-linked cationic multi-block copolymers for gene delivery and methods of making thereof
WO2006048017A1 (en) 2004-11-03 2006-05-11 Liplasome Pharma A/S Lipid-based drug delivery systems containing unnatural phospholipase a2 degradable lipid derivatives and the therapeutic uses thereof
US7964571B2 (en) 2004-12-09 2011-06-21 Egen, Inc. Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases
US20120269886A1 (en) 2004-12-22 2012-10-25 Nitto Denko Corporation Therapeutic agent for pulmonary fibrosis
DK1842557T3 (da) 2004-12-22 2013-12-02 Nitto Denko Corp Lægemiddelbærer og lægemiddelbærerkit til inhibition af fibrose
JP4533420B2 (ja) 2004-12-22 2010-09-01 日東電工株式会社 線維化抑制のための薬物担体および薬物担体キット
JP2009221164A (ja) 2008-03-17 2009-10-01 Nitto Denko Corp 肺線維症処置剤
US7404969B2 (en) 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
US8246983B2 (en) * 2005-09-02 2012-08-21 Northwestern University Encapsulated arsenic drugs
JP5342834B2 (ja) 2008-09-05 2013-11-13 日東電工株式会社 骨髄線維症処置剤
US7700541B2 (en) 2006-04-06 2010-04-20 Nitto Denko Corporation Biodegradable cationic polymers
US8808681B2 (en) 2006-06-05 2014-08-19 Massachusetts Institute Of Technology Crosslinked, degradable polymers and uses thereof
TWI407971B (zh) 2007-03-30 2013-09-11 Nitto Denko Corp Cancer cells and tumor-related fibroblasts
US20080312174A1 (en) 2007-06-05 2008-12-18 Nitto Denko Corporation Water soluble crosslinked polymers
AU2008298592A1 (en) 2007-09-14 2009-03-19 Nitto Denko Corporation Drug carriers
KR20110051214A (ko) 2008-07-30 2011-05-17 닛토덴코 가부시키가이샤 약물 담체

Also Published As

Publication number Publication date
EP2135600A1 (en) 2009-12-23
JP2017048225A (ja) 2017-03-09
CA2682493A1 (en) 2008-10-09
KR101585947B1 (ko) 2016-01-15
KR20090130010A (ko) 2009-12-17
US8686052B2 (en) 2014-04-01
AU2008233550B2 (en) 2013-02-21
CN101674810B (zh) 2014-07-16
ES2793673T3 (es) 2020-11-16
WO2008120815A1 (ja) 2008-10-09
EP2135600B1 (en) 2020-04-29
AU2008233550A1 (en) 2008-10-09
CN101674810A (zh) 2010-03-17
JP2015134789A (ja) 2015-07-27
TW200846022A (en) 2008-12-01
JP5302187B2 (ja) 2013-10-02
JP2013224311A (ja) 2013-10-31
EP2135600A4 (en) 2013-10-16
JPWO2008120815A1 (ja) 2010-07-15
TWI407971B (zh) 2013-09-11
US20140127187A1 (en) 2014-05-08
US20100144659A1 (en) 2010-06-10

Similar Documents

Publication Publication Date Title
AR065878A1 (es) Agente con blanco en una celula cancerosa y un fibroblasto asociado a cancer
Berindan-Neagoe et al. Molecular pathways: microRNAs, cancer cells, and microenvironment
Banelli et al. MicroRNA in glioblastoma: an overview
FI3604532T3 (fi) Uusia crispr-entsyymejä ja järjestelmiä
EP4310196A3 (en) Methods and compositions for manipulating nucleic acids
JP2010138188A5 (es)
PE20190843A1 (es) Arn de direccion a adn generico
Beauchemin et al. Dynamic microRNA-101a and Fosab expression controls zebrafish heart regeneration
WO2016106400A3 (en) Rna interference agents for gst-pi gene modulation
HRP20231022T1 (hr) Hibridni polinukleotidi crispr dna/rna i načini uporabe
BR112015022507A2 (pt) ácidos ribonucleicos com nucleotídeos 4'-tio-modificados, composição compreendendo o mesmo e usos relacionados
ATE544774T1 (de) Rnai-modulation von mll-af4 und verwendungen dafür
WO2009142822A3 (en) 2-f modified rna interference agents
HK1252970A1 (zh) 确定的多偶联寡核苷酸
EA201891629A1 (ru) Способы и композиции для повышения эффективности нацеленной модификации генов с применением опосредуемой олигонуклеотидами репарации генов
WO2010080129A3 (en) Extended dicer substrate agents and methods for the specific inhibition of gene expression
WO2004009769A3 (en) COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF ANGIOGENESIS
WO2012024396A3 (en) Compositions and methods for delivering nucleic acid molecules and treating cancer
WO2011056073A3 (en) Novel compounds for modulating neovascularisation and methods of treatment using these compounds
BR112021007403A2 (pt) Composições e métodos para entrega de transgenes
JP2013046616A5 (es)
PE20140647A1 (es) Metodo para tratamiento de cancer de pulmon de celulas no pequenas
EP4218770A3 (en) Compositions and processes for targeted delivery, expression and modulation of coding ribonucleic acids in tissue
BRPI0517131A2 (pt) mÉtodos para simplificar Ácidos nuclÉicos microbiais por modificaÇço quÍmica de citosinas
PH12021551025A1 (en) 5-halouracil-modified micrornas and their use in the treatment of cancer

Legal Events

Date Code Title Description
FA Abandonment or withdrawal